Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1-27) in XXXX in vivo.

@entity3045 @entity840 @entity20530 @entity112
1. We studied the inhibitory effect of pituitary adenylate cyclase activating polypeptide (PACAP 1-27) on the increase in total pulmonary resistance (RL) caused either by allergen or @entity112 in anaesthetized, ventilated @entity840 . 2. PACAP 1-27 given via i.v. infusion (0.045-4.5 nmol kg-1 min-1) dose-dependently reduced the increase in RL caused by inhaled ovalbumin and @entity112 . At the highest dose, PACAP 1-27 prevented the increase in RL caused by ovalbumin and @entity112 completely. Infusion of PACAP 1-27 and the @entity20530 agonist, @entity3045 (0.045-4.5 nmol kg-1 min-1) inhibited the increase in RL similarly, but @entity3045 increased the heart rate more than PACAP 1-27. 3. PACAP 1-27 and @entity3045 given via inhaled aerosol (0.1 mM, 20 breaths) significantly reduced the increase in RL caused by @entity112 infused i.v., whereas aerosolised sterile saline did not. Both PACAP 1-27 and @entity3045 caused bronchodilator effects within 1 min of drug inhalation and these effects remained throughout the 20 min of study. 4. Because PACAP 1-27 produced significant bronchodilatation and rapid onset of sustained action in vivo and without pronounced cardiovascular side effects, we conclude that this peptide may have therapeutic potential as a bronchodilator.
